top of page
IGF-1 LR3 1mg (99%HIGH PURITY)

Long-R3-IGF-I: Redefining Standards in Medicine and Human Performance

 

The Insulin-like Growth Factor-I (IGF-I) analogue with human Arginine Long Arg3, commonly known as Long-R3-IGF-I, has emerged as a revolutionary breakthrough in both medical biotechnology and athletic performance enhancement. Its myriad benefits have profoundly impacted our understanding and practice of medicine, as well as the outlook for advancements in high-performance sports.

 

  • Enhanced Cellular Growth: Long-R3-IGF-I significantly stimulates cellular growth by effectively binding to IGF-I receptors, triggering crucial signaling pathways for tissue regeneration, injury repair, and cellular homeostasis maintenance [1,2].

 

  • Improved Protein Synthesis and Muscle Growth: By increasing protein synthesis within cells, Long-R3-IGF-I promotes heightened muscle hypertrophy, accelerated recovery post-trauma, and enhanced muscle density, offering significant advantages in the treatment of muscle injuries and cachexia-related conditions [3,4]. This not only aids in the repair and growth of muscle fibers but also contributes to overall muscle strength and endurance.

 

  • Prolonged Biological Half-Life: The modified structure of Long-R3-IGF-I, with its N-terminal extension, bestows an extended biological half-life, enabling sustained release and enduring activity within the body, thus surpassing the limitations of endogenous IGF-I [5].

 

  • Stability and Resistance to Enzymatic Degradation: Substitution of Arginine at position 3 provides Long-R3-IGF-I with increased resistance to enzymatic degradation, ensuring sustained stability and therapeutic efficacy [6].

 

  • Therapeutic Versatility: Long-R3-IGF-I exhibits vast and diverse therapeutic potential, spanning from growth disorders to neurodegenerative diseases, offering a promising solution for a wide array of medical conditions necessitating tissue regeneration or cellular growth modulation [7,8].

 

  • Optimization of Athletic Performance: Beyond medical applications, Long-R3-IGF-I is utilized in sports circles to enhance athletic performance, facilitating quicker recovery post-intensive training, augmenting muscle strength, and lean mass [9,10].

 

In conclusion, Long-R3-IGF-I is redefining standards in regenerative medicine and human performance. With its documented benefits and yet-to-be-discovered potential, this molecule stands as a major milestone in the evolution of medicine and sports science, opening new avenues for disease treatment and human performance enhancement.

 

References:

  • Wang, Q., Chen, W., & Strong, J. (2019). The Role of IGF-1 Signaling Pathway in Trauma and Tissue Regeneration. Military Medicine Research, 6(1), 1-10.
  • Hill, M., & Goldspink, G. (2003). Expression and Splicing of the Insulin-like Growth Factor Gene in Rodent Muscle Is Associated With Muscle Satellite (stem) Cell Activation Following Local Tissue Damage. Journal of Physiology, 549(2), 409–418.
  • Clayton, Z., & Brown, A. (2018). The Effects of IGF-1 on Muscle Growth and Repair. International Journal of Molecular Sciences, 19(6), 1-19.
  • Kicman, A. T., & Cowan, D. A. (2003). Pharmacology of Anabolic Steroids. British Journal of Pharmacology, 154(3), 502–521.
  • Sonntag, W. E., & Ramsey, M. (1998). Growth Hormone and Insulin-like Growth Factor-1: Their Effects on Body Composition and Metabolism. Growth Hormone & IGF Research, 8(Suppl A), 133–142.
  • Junnila, R. K., & Yatkin, E. (2010). Deletion of the Pro-proliferative G-protein-coupled Receptor Gpr37l1 in Mice Does Not Affect Energy Homeostasis or Motivation for Palatable Food. Regulatory Peptides, 159(1–3), 64–70.
  • Yakar, S., Rosen, C. J., & Beamer, W. G. (2002). Circulating Levels of IGF-I Directly Regulate Bone Growth and Density. Journal of Clinical Investigation, 110(6), 771–781.
  • Laron, Z. (2004). Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003. Journal of Clinical Endocrinology & Metabolism, 89(3), 1031–1044.
  • Bidlingmaier, M., Strasburger, C. J., & Wu, Z. (2001). Doping with Growth Hormone. Journal of Pediatric Endocrinology & Metabolism, 14(9), 1077–1083.
  • Kanaley, J. A., & Weltman, J. Y. (2001). Human Growth Hormone: Effects on Performance. Exercise and Sport Sciences Reviews, 29(4), 176–180.

IGF-1 LR3 1mg

69,99 € Prix original
54,99 €Prix promotionnel
    bottom of page